Vir Biotechnology (VIR) Equity Income (2021 - 2026)
Vir Biotechnology recorded quarterly Equity Income of -$170000.0 in Q1 2026, up 93.46% quarter-over-quarter from -$2.6 million in Q4 2025, and down 102.66% year-over-year from $6.4 million in Q1 2025.
Vir Biotechnology's Equity Income history runs 6 years deep, the most recent figure standing at -$170000.0 for Q1 2026.
- In Q1 2026, Equity Income fell 102.66% year-over-year to -$170000.0; the TTM figure through Mar 2026 stood at -$4.8 million (down 171.47% YoY), while the FY2025 annual figure was $1.7 million, up 130.75% from the prior year.
- Equity Income came in at -$170000.0 for Q1 2026 at Vir Biotechnology, up from -$2.6 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of $8.9 million in Q4 2022 to a low of -$95.0 million in Q1 2022.
- A 5-year average of -$8.1 million and a median of -$2.6 million in 2025 frame the typical range for Equity Income.
- On a YoY basis, Equity Income climbed as much as 207.9% in 2025 and fell as far as 945.5% in 2025.
- Vir Biotechnology's Equity Income stood at $8.9 million in 2022, then plunged by 111.26% to -$1.0 million in 2023, then retreated by 16.73% to -$1.2 million in 2024, then slumped by 121.84% to -$2.6 million in 2025, then jumped by 93.46% to -$170000.0 in 2026.
- According to Business Quant data, Equity Income over the past three periods registered -$170000.0, -$2.6 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -170,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -170,000.00 |
| Dec 31, 2025 | -2.60 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | -3.38 Mn |
| Mar 31, 2025 | 6.38 Mn |
| Dec 31, 2024 | -1.17 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | -5.92 Mn |
| Dec 31, 2023 | -1.00 Mn |
| Sep 30, 2023 | -2.70 Mn |
| Jun 30, 2023 | -5.09 Mn |
| Mar 31, 2023 | -13.10 Mn |
| Dec 31, 2022 | 8.92 Mn |
| Sep 30, 2022 | -13.59 Mn |
| Jun 30, 2022 | -11.39 Mn |
| Mar 31, 2022 | -95.04 Mn |
| Dec 31, 2021 | -26.02 Mn |
| Sep 30, 2021 | 164.07 Mn |